# C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

> **NCT01530269** · PHASE2 · COMPLETED · sponsor: **Phoenix Molecular Imaging** · enrollment: 300 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** C11-Sodium Acetate

## Key facts

- **NCT ID:** NCT01530269
- **Lead sponsor:** Phoenix Molecular Imaging
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530269, "C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01530269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*